Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre.
children
corticosteroids
haemolysis
sickle cell disease
transfusion
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
11
10
2022
accepted:
02
12
2022
medline:
29
3
2023
pubmed:
22
12
2022
entrez:
21
12
2022
Statut:
ppublish
Résumé
Delayed haemolytic transfusion reaction (DHTR) is a life-threatening haemolytic anaemia following red blood cell transfusion in patients with sickle cell disease, with only scarce data in children. We retrospectively analysed 41 cases of DHTR in children treated between 2006 and 2020 in a French university hospital. DHTR manifested at a median age of 10.5 years, symptoms occurred a median of 8 days after transfusion performed for an acute event (63%), before surgery (20%) or in a chronic transfusion programme (17%). In all, 93% of patients had painful crisis. Profound anaemia (median 49 g/L), low reticulocyte count (median 140 ×10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-132Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primer. 2018;4(1):18010.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429-39.
Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323-33.
Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-81.
Narbey D, Habibi A, Chadebech P, Mekontso-Dessap A, Khellaf M, Lelièvre JD, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-8.
Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746-53.
Habibi A, Mekontso-Dessap A, Guillaud C, Michel M, Razazi K, Khellaf M, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes: DHTR in SCD patients. Am J Hematol. 2016;91(10):989-94.
de Montalembert M, Dumont MD, Heilbronner C, Brousse V, Charrara O, Pellegrino B, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801-7.
Talano JAM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111(6):e661-5.
Falguière C, Allali S, Khazem B, Kamdem A, Arnaud C, Belloy M, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease: first five-year retrospective study in mainland France. Haematologica. 2022. Online ahead of print.
Thein SL, Pirenne F, Fasano RM, Habibi A, Bartolucci P, Chonat S, et al. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica. 2020;105(3):539-44.
Stowell SR, Winkler AM, Maier CL, Arthur CM, Smith NH, Girard-Pierce KR, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol. 2012;2012:1-12.
Merle NS, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina LT. Complement activation during intravascular hemolysis: implication for sickle cell disease and hemolytic transfusion reactions. Transfus Clin Biol. 2019;26(2):116-24.
Arthur CM, Chonat S, Fasano R, Yee MEM, Josephson CD, Roback JD, et al. Examining the role of complement in predicting, preventing, and treating hemolytic transfusion reactions. Transfus Med Rev. 2019;33(4):217-24.
Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-55.
Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-65.
The International Society of Nephrology. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1.
Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166(2):165-76.
Stotesbury H, Kawadler JM, Hales PW, Saunders DE, Clark CA, Kirkham FJ. Vascular instability and neurological morbidity in sickle cell disease: an integrative framework. Front Neurol. 2019;10:871.
Mekontso Dessap A, Pirenne F, Razazi K, Moutereau S, Abid S, Brun-Buisson C, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181-4.
Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-37.
Chiaroni J, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, et al. HLA-DRB1 polymorphism is associated with Kell immunisation: HLA-DRB1 polymorphism and Kell immunisation. Br J Haematol. 2006;132(3):374-8.
Yazdanbakhsh K. FcγR and SCD alloimmunization: a nonclass(ical) act. Blood. 2017;130(19):2051-2.
Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica. 2015;100(11):1415-25.
Pal M, Bao W, Wang R, Liu Y, An X, Mitchell WB, et al. Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease. Blood. 2021;137(2):269-80.
Covington ML, Cone-Sullivan JK, Andrzejewski C, Lu W, Thomasson RR, O'Brien K, et al. Unmasking delayed hemolytic transfusion reactions in patients with sickle-cell disease: challenges and opportunities for improvement. Transfusion (Paris). 2022;62(8):1662-70.
Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-71.
Silvy M, Tournamille C, Babinet J, Pakdaman S, Cohen S, Chiaroni J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014;99(7):e115-7.
Floch A, Morel A, Zanchetta-Balint F, Cordonnier-Jourdin C, Allali S, Grall M, et al. Treatment of delayed hemolytic transfusion reactions in sickle cell disease patients by an anti-C5 antibody. Blood. 2019;134(Suppl 1):2458-8.
Zanchetta-Balint F, Pirenne F, Michel M, Mekontso-Dessap A, Mahevas M, Guillaud C, et al. Rituximab for preventing delayed hemolytic transfusion reaction (DHTR) in sickle cell adult patients: outcome of transfusion and side effects in 58 cases. Blood. 2019;134(Suppl_1):3687-7.
Noizat-Pirenne F, Habibi A, Mekontso-Dessap A, Razazi K, Chadebech P, Mahevas M, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang. 2015;108(3):262-7.